Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q1 2012 venture financing round-up: ortho bucks investment trend and overtakes heart firms

This article was originally published in Clinica

Executive Summary

The arid, post-credit crunch IPO market may be on its way to becoming a hazy memory as the flow of successful medtech floats look to be strengthening as we move well into the first half of 2012. Already, there has been the €38m ($49.6m) flotation of orthopaedics imaging specialist EOS Imaging on the EuroNext (www.clinica.co.uk, 17 February 2012), while Osprey Medical raised Aus$20 ($21m) in its IPO on the Australian Stock Exchange (www.clinica.co.uk, 19 April 2012). There are even more ambitious flotations in the pipeline, such as spinal implant firm Globus's plans to raise $100m in an IPO on the NYSE (www.clinica.co.uk, 2 April 2012) while just this week (7 May), cancer diagnostics firm Cancer Genetics announced it was looking to bag around $48m from its planned IPO on the Nasdaq.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel